Taiwan’s First: YODA-KY (7829) AI-Developed Drug Prioritized by iLCT for Parkinson’s Disease Development; Signs MOUs with Australia and New Zealand to Expand Clinical Reach
TAIPEI, March 27, 2026 — Focusing on the use of artificial intelligence (AI) to develop new drugs for the central nervous system (CNS), Cayman Islands-based Yoda Pharmaceuticals Inc. (hereinafter referred to as YODA-KY, stock code 7829) announced today (27) that its subsidiary, Dasher Neuroscience Inc. (formerly Yoda therapeutics Inc.), has been selected by the International Linked Clinical Trials (iLCT) program for its Priority List for Parkinson’s disease clinical development. This marks the first time a Taiwan-developed drug has been included, underscoring strong recognition from leading global Parkinson’s disease experts. In addition, the company has signed separate Memorandum of Understandings (MOUs) with the Shake It Up Australia Foundation and with The Movement Disorders Society of Australia and New Zealand Clinical Trials Network (MDSANZ CTN). The partnerships are expected to provide access to international funding and clinical trial resources, accelerating the global development and commercialization of its innovative therapy. The company is actively evaluating plans to initiate global clinical trials in early 2027.
Following a rigorous evaluation by a committee of over 25 top international Parkinson’s experts, Dasher Neuroscience’s AI drug for neurodegenerative diseases was selected for the iLCT program, a joint initiative by the UK Parkinson’s research charity Cure Parkinson’s and the US-based Van Andel Institute (VAI). Now officially included in the Priority List for Parkinson’s disease clinical development, the drug is poised to potentially receive clinical trial funding from Cure Parkinson’s in the future.
Since 2012, the iLCT program has invested £10.3 million (approximately NT$438 million) to support the development of various Parkinson’s therapies and diagnostics, recruiting over 4,700 Parkinson’s patients globally for related clinical trials. The program has completed 21 Parkinson’s clinical trials, with another 20 currently underway.
Being selected for iLCT Parkinson’s priority list highlights the novelty, therapeutic potential, and R&D capabilities of its AI-developed therapy for neurodegenerative diseases, while also placing the company on the global Parkinson’s research map.
Following this milestone, Dasher Neuroscience has initiated strategic collaborations with the Shake It Up Australia Foundation and the Movement Disorders Society of Australia and New Zealand Clinical Trials Network (MDSANZ CTN). Through this partnership, the Shake It Up Australia Foundation is expected to provide funding support for Dasher Neuroscience’s planned clinical trials in Australia.
Jane Tseng, CEO of Dasher Neuroscience, stated that the Shake It Up Australia Foundation is the largest non-governmental organization funding Parkinson’s research in Australia. The foundation collaborates with the Michael J. Fox Foundation (MJFF), the world’s largest private funder of Parkinson’s research, to advance promising Parkinson’s therapies into clinical trials. To date, the Shake It Up Australia Foundation has provided funding to 23 research institutions and supported up to 79 research projects in Australia, with total grants exceeding AU$30 million (approximately NT$680 million).
Moreover, through close collaboration with the MDSANZ CTN, Dasher Neuroscience is expected to leverage its extensive network of hospitals and research centers across Australia and New Zealand. This will facilitate large-scale, cross-regional matching of patient and physician resources, enhance patients’ access to clinical trials for movement disorders, and accelerate trial execution.
Jane Tseng noted that the company’s AI-developed therapy for neurodegenerative diseases has consecutively received recognition and support from iLCT, the Shake It Up Australia Foundation, and the Movement Disorders Society of Australia and New Zealand Clinical Trials Network (MDSANZ CTN). This strong backing will significantly help the company connect with leading Parkinson’s disease experts worldwide and accelerate the implementation of clinical trials at prominent medical centers across multiple countries. At the same time, it reflects Taiwan’s emergence into the global first-tier of Parkinson’s drug development.
About YODA Pharmaceuticals Inc. (YODA-KY)
YODA–KY (7829), listed on the Emerging Stock Board on June 3, 2025, is a biopharmaceutical company focused on AI-driven drug discovery and the development of therapies for CNS disorders.
The company’s flagship drug, YA-101, is initially targeting multiple system atrophy (MSA) and is currently in Phase II clinical trials. YA-101 has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation (ODD) in the U.S., Japan, and the EU. Additionally, YA-102, for Parkinson’s disease, is under development. The company is also advancing two preclinical drug candidates: YA-201 for Alzheimer’s disease and YA-301 for schizophrenia.
Committed to addressing significant unmet medical needs, YODA–KY focuses on providing innovative, safe, and effective therapeutic solutions. For more information, please visit: www.dasherneuroscience.com.